Skin cancer is the most common cancer in the United States.1,2 The incidence of skin cancer (basal cell, squamous cell, and melanoma) has been on the rise for a number of years. This increase is likely due to a combination of factors: more awareness and screening, better detection, increased longevity, and more sun exposure.3
Estimates are that nonmelanoma skin cancers, which include basal cell and squamous cell carcinomas, affect over 3 million Americans a year.4 Of the two, basal cell carcinoma is more common. Both of these types of skin cancer rarely spread to other parts of the body and are curable when detected early and treated appropriately.
Melanoma, although far less common, is much more likely to spread to other parts of the body. While only 1 percent of skin cancers are melanomas, this type of skin cancer is responsible for the majority of skin cancer deaths.1
Most skin cancers in the U.S. are basal cell carcinoma (BCC) or squamous cell carcinoma (SCC), with BCC being the most common. Because SCC occurs less often, providers in the community are less likely to diagnose and treat patients with advanced cutaneous squamous cell carcinoma (cSCC) on a regular basis.
Low-risk cSCC is often effectively treated with a variety of surgical modalities. However, 2 - 5 percent of cSCCs metastasize to regional lymph nodes or more distant sites. Advanced/metastatic cSCC is a rare and complex disease that requires dedicated multidisciplinary management.
A developed publication provides updates on advanced cSCC treatment and features three regionally diverse cancer programs that are exploring best practices in caring for patients with advanced cSCC. Access the publication and learn about tools and resources for Multidisciplinary Advanced Cutaneous Squamous Cell Carcinoma Care.